Subscribe

Shitanshu Uppal

NRG-GY023: Durvalumab, Olaparib, and Cediranib vs Chemotherapy in Platinum-Resistant Ovarian Cancer with Prior Bevacizumab

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

One Hundred Posts: GYOEDU Website Updates

Publications Update # 99

Managing perfectionism, conization prior to open radical hysterectomy, KELIM score in ovarian cancer with mini-video tutorial

Welcome to GYOEDU

Hi there! 🌟 As a valued member of the GYOEDU community,

Publications Update # 98

"Have you been there?" an award winning speech, INSPIRE-4 clinical trial discussing intra-abdominal infection treatment, Phase 2 LIGHT study exploring PARPs in ovarian cancer, link to a prior PARP tutorial, consolidation cycles in GTN treatment

Tumor Board

Feedback Action Plan

Resident Assessment Quiz - Ovarian Cancer

Question 1: Which immunohistochemical marker is most helpful in supporting

GYOEDU Chatbot

Publications Update # 97

Taylor Swift and her business, venous thromboembolism in cancer patients - duration of treatment, dose of pembrolizumab and lenvatinib, metformin in endometrial cancer, and the cost of ADCs